

## The novel 2016 WHO *Neisseria gonorrhoeae* reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization

Magnus Unemo<sup>1\*</sup>, Daniel Golparian<sup>1</sup>, Leonor Sánchez-Busó<sup>2</sup>, Yonatan Grad<sup>3,4</sup>, Susanne Jacobsson<sup>1</sup>, Makoto Ohnishi<sup>5</sup>, Monica M. Lahra<sup>6</sup>, Athena Limnios<sup>6</sup>, Aleksandra E. Sikora<sup>7</sup>, Teodora Wi<sup>8</sup> and Simon R. Harris<sup>2</sup>

<sup>1</sup>WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, National Reference Laboratory for Pathogenic *Neisseria*, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; <sup>2</sup>Pathogen Genomics, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridgeshire, UK; <sup>3</sup>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA; <sup>4</sup>Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; <sup>5</sup>Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan; <sup>6</sup>WHO Collaborating Centre for Sexually Transmitted Diseases, Department of Microbiology, South Eastern Area Laboratory Services, The Prince of Wales Hospital, Randwick, Sydney, Australia; <sup>7</sup>Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR, USA; <sup>8</sup>Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland

\*Corresponding author. Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, SE-701 85 Örebro, Sweden. Tel: +46-19-6022038; Fax: +46-19-127416; E-mail: magnus.unemo@regionorebrolan.se

Received 15 March 2016; returned 21 April 2016; revised 2 June 2016; accepted 11 June 2016

**Objectives:** Gonorrhoea and MDR *Neisseria gonorrhoeae* remain public health concerns globally. Enhanced, quality-assured, gonococcal antimicrobial resistance (AMR) surveillance is essential worldwide. The WHO global Gonococcal Antimicrobial Surveillance Programme (GASP) was relaunched in 2009. We describe the phenotypic, genetic and reference genome characteristics of the 2016 WHO gonococcal reference strains intended for quality assurance in the WHO global GASP, other GASPs, diagnostics and research worldwide.

**Methods:** The 2016 WHO reference strains ( $n=14$ ) constitute the eight 2008 WHO reference strains and six novel strains. The novel strains represent low-level to high-level cephalosporin resistance, high-level azithromycin resistance and a *porA* mutant. All strains were comprehensively characterized for antibiogram ( $n=23$ ), serovar, prolyliminopeptidase, plasmid types, molecular AMR determinants, *N. gonorrhoeae* multiantigen sequence typing STs and MLST STs. Complete reference genomes were produced using single-molecule PacBio sequencing.

**Results:** The reference strains represented all available phenotypes, susceptible and resistant, to antimicrobials previously and currently used or considered for future use in gonorrhoea treatment. All corresponding resistance genotypes and molecular epidemiological types were described. Fully characterized, annotated and finished reference genomes ( $n=14$ ) were presented.

**Conclusions:** The 2016 WHO gonococcal reference strains are intended for internal and external quality assurance and quality control in laboratory investigations, particularly in the WHO global GASP and other GASPs, but also in phenotypic (e.g. culture, species determination) and molecular diagnostics, molecular AMR detection, molecular epidemiology and as fully characterized, annotated and finished reference genomes in WGS analysis, transcriptomics, proteomics and other molecular technologies and data analysis.

### Introduction

Gonorrhoea is a public health concern globally.<sup>1,2</sup> The impact of antimicrobial resistance (AMR) in *Neisseria gonorrhoeae* (gonococci) on the treatment and control of gonorrhoea is a longstanding concern. In the last decade, while retaining AMR to previously used therapeutic drugs, gonococci have developed resistance,

including high-level resistance, to the last option for empirical antimicrobial monotherapy, the extended-spectrum cephalosporin (ESC) ceftriaxone.<sup>3–10</sup> Rare failures to treat pharyngeal gonorrhoea with ceftriaxone were verified in several countries.<sup>3,5,11–14</sup>

In response, the WHO,<sup>2</sup> CDC<sup>15</sup> and ECDC<sup>16</sup> have published global and regional action plans to control the transmission and impact of MDR and XDR gonorrhoea. A key component of these

plans is to enhance the surveillance of gonococcal AMR locally, nationally and internationally. The WHO global Gonococcal Antimicrobial Surveillance Programme (GASP) was relaunched in 2009.<sup>2,17</sup> The WHO GASP works in liaison with other GASPs. For example, Euro-GASP is acting in the European Union and European Economic Area<sup>18,19</sup> and national GASPs are active in the USA<sup>20</sup> (<http://www.cdc.gov/std/gisp>), UK<sup>21</sup> (<http://www.hpa.org.uk/Publications/InfectiousDiseases/HIVandSTIs/GRASPreports/>) and many additional countries. This enhanced gonococcal AMR surveillance should monitor trends in resistance, identify newly emerging AMR and inform treatment guidelines in a timely fashion. However, reliable, quality assured and nationally and internationally comparable AMR data are essential. In the absence of uniform AMR testing methodology globally (method parameters, agar media and resistance breakpoints), inter-laboratory comparisons of AMR data are enabled through the use of international reference strains.<sup>22,23</sup> The WHO Collaborating Centre in Örebro, Sweden and the WHO Collaborating Centre in Sydney, Australia have undertaken continuing assessments over many years to select, evaluate and nominate suitable gonococcal strains for use in the internal quality control and external quality assurance of national, WHO regional and international GASPs and for other purposes. In 2009, the 2008 WHO gonococcal reference strains were published.<sup>23</sup> The characterizations of these reference strains ( $n=8$ ) were substantially expanded in the present study. Furthermore, due to the emergence of ESC resistance and high-level azithromycin resistance, five additional strains (with low-level to high-level resistance to ESCs, including resistance associated with ESC treatment failures, and azithromycin) have now been added to the WHO reference strain panel. In recent years, gonococcal *porA* mutants containing *N. meningitidis porA* gene sequences that result in false-negative results in *porA*-based gonococcal nucleic acid amplification tests (NAATs) have been described in several countries.<sup>24,25</sup> One such gonococcal *porA* mutant has also been included among the 2016 WHO gonococcal reference strains ( $n=14$ ).

This study characterized the 2016 WHO *N. gonorrhoeae* reference strains phenotypically [antibiograms, serovars and prolyliminopeptidase (PIP) production] and genetically [AMR plasmid types, molecular resistance determinants, *N. gonorrhoeae* multi-antigen sequence typing (NG-MAST) STs and MLST STs] and presents finished, fully characterized and annotated reference genomes, which will be exceedingly valuable for quality assurance of WGS, transcriptomics, proteomics and other molecular technologies and data analysis. The 2016 WHO gonococcal reference strains are intended for internal and external quality assurance and quality control in all types of laboratory examinations, particularly in the AMR testing (phenotypic and genetic) in GASPs, as recommended for the WHO global GASP, but also for phenotypic (e.g. culture) and genetic (e.g. NAATs) diagnostics, species determination, genetic AMR detection, molecular epidemiology and genomics.

## Materials and methods

### Bacterial strains

The 2016 WHO gonococcal reference strains include the previously published 2008 WHO gonococcal reference strains (WHO F, G, K, L, M, N, O and P)<sup>23</sup> and six additional, strictly selected gonococcal strains. The new strains were designated as WHO U (Sweden, 2011),<sup>25</sup> WHO V (Sweden, 2012),<sup>26</sup> WHO W (Hong Kong, 2007),<sup>27</sup> WHO X (H041; Japan, 2009),<sup>5</sup>

WHO Y (F89; France, 2010)<sup>7</sup> and WHO Z (A8806; Australia, 2013).<sup>8</sup> All strains were cultivated and preserved as described.<sup>28</sup> All the 2016 WHO gonococcal reference strains ( $n=14$ ) are available at the National Collection of Type Cultures (NCTC; [www.phe-culturecollections.org.uk](http://www.phe-culturecollections.org.uk)) under the NCTC numbers 13477–13484, 13817–13822 (Table 1).

### Serogroup and serovar determination

Serogroup and serovar determination using PhadeBact GC Monoclonal Serovar Test (Bactus AB, Stockholm, Sweden) were performed as described.<sup>29</sup>

### Detection of PIP

PIP production was detected using API NH (bioMérieux, Marcy-l'Étoile, France), according to the manufacturer's instructions.

### Antimicrobial susceptibility testing

MICs of 20 antimicrobials were determined using the Etest method (bioMérieux, Solna, Sweden), according to the manufacturer's instructions, on GCRAP agar plates [3.6% Difco GC Medium Base agar (BD Diagnostics, Sparks, MD, USA) supplemented with 1% haemoglobin (BD) and 1% IsoVitalax (BD)]. MICs of solithromycin,<sup>4,14</sup> zoliflodacin (also known as ETX0914 and AZD0914)<sup>4,14</sup> and thiamphenicol were determined using the agar dilution method as previously described. Where breakpoints were available, the susceptible (S), intermediate susceptibility (I) and resistance (R) categorization was based on the interpretative criteria from EUCAST ([www.eucast.org](http://www.eucast.org)). For the antimicrobials where EUCAST does not state any breakpoints, only the consensus MIC values are presented (Table 1). For all strains and antimicrobials, each determination was performed at least three times using new bacterial suspensions on separate batches of agar plates and the consensus MIC was reported.  $\beta$ -Lactamase production was detected using nitrocefin solution (Oxoid, Basingstoke, UK).

### Isolation of bacterial DNA

Genomic DNA was isolated using the Wizard Genomic DNA Purification Kit (Promega Corporation, Madison, WI, USA), according to the manufacturer's instructions. Purified DNA was stored at 4°C prior to genetic analysis.

### Conventional sequencing

The PCRs, purification of PCR amplicons and conventional sequencing of genes associated with diagnostics, AMR and molecular epidemiology were performed as described.<sup>23</sup>

Sequence alignments were performed using the BioEdit Sequence Alignment Editor (v. 7.0.9.0) software (Ibis Biosciences, Carlsbad, CA, USA). Determinations of NG-MAST STs and MLST STs were performed as described previously.<sup>23,29,30</sup> All genes and determinants (Table 2) were also identified *in silico* from the WGS data.

### Genome sequencing

Single-molecule, real-time (SMRT) DNA genome sequencing was performed using the PacBio RS II (Pacific Biosciences, Menlo Park, CA, USA) with P5-C3 chemistry, resulting in average sub-read lengths of 28476 bp. One or two SMRT cells were used for each strain to provide high coverage levels for each (average of 165×) (Table S1, available as Supplementary data at JAC Online).

*De novo* assembly of the genomes was conducted using the hierarchical genome assembly process (HGAP3, SMRTAnalysis 2.3.0) workflow. Full chromosome sequences were circularized using Circlator<sup>31</sup> and then

further corrected using Quiver.<sup>32</sup> WHO F and WHO K were manually circularized and corrected with Quiver.<sup>32</sup>

Because large fragments are selected during PacBio library preparation and the longest reads are selected for assembly by the HGAP pipeline, not all plasmids were retrieved in the HGAP assemblies. The cryptic plasmid was not retrieved in six strains (WHO N, O, P, U, V and Z) and the Asian pBlaTEM plasmid in WHO N. Accordingly, Illumina sequencing was also performed on the 14 strains using the HiSeq 2000 2×100 bp platform. Reads were assembled using a pipeline (<https://github.com/sanger-pathogens/vr-codebase>) developed at the Wellcome Trust Sanger Institute.<sup>33</sup> The missing plasmids were detected as single contigs directly from the Illumina assemblies using ACT.<sup>34</sup> They were circularized manually using the other strains as references.

As a second check, the three types of plasmid detected (pCryptic, pBlaTEM and pConjugative) were compared with their corresponding references in public databases (pJD1, pJD4 and pEP5289, respectively) by mapping all PacBio filtered sub-reads against the reference using BWA MEM.<sup>35</sup> Mapped reads were extracted from the bam files and assembled independently using minimap and miniasm,<sup>36</sup> and the resulting unigigs corrected using Quiver.<sup>32</sup> The initial, Illumina, assemblies of the WHO N and WHO V Asian pBlaTEM plasmids were found to be missing a 1.8 kb region compared with the resulting assemblies from miniasm and the Asian reference plasmid. Thus, miniasm corrected assemblies were used for subsequent steps in these two cases.

Full chromosomes and plasmids were annotated using PROKKA v. 1.11<sup>37</sup> followed by manual curation using Artemis.<sup>38</sup> Additional proteins annotated in *N. gonorrhoeae* FA1090 but not identified in the automatic annotation were checked manually and added when appropriate. InterProScan<sup>539</sup> was used to improve annotation of hypothetical proteins. Sequence data for each strain has been deposited in the ENA under BioProject accession no. PRJEB14020.

Genomes were compared through BLAST<sup>40</sup> analyses and visualized using BRIG v. 0.95.<sup>41</sup> The core genome of the 14 references was obtained using Roary.<sup>42</sup> Pairwise core SNPs were calculated and a minimum evolution tree computed using MEGA v6.<sup>43</sup>

## Results

### Phenotypic characterization

Three (21%) and 11 (79%) of the strains were assigned as serogroup PorB1a (WI) and PorB1b (WII/III), respectively, and in total eight serovars were represented (Table 1). Three (21%) of the strains (WHO G, N and V) were PIP-negative. Four (29%) of the strains (WHO M, N, O and V) produced β-lactamase. The consensus MIC and, where feasible, SIR categorization for each antimicrobial and strain, and the range of MICs for all strains, as determined by the single method used, are also presented. The strains represented all important susceptible, intermediate susceptible and resistant phenotypes and the ranges of resistances seen for most antimicrobials previously or currently recommended in different guidelines, used in gonorrhoea treatment globally or considered for future use. These included strains with high-level resistance to penicillin G, ampicillin, temocillin, ceftriaxone, cefixime, cefuroxime, azithromycin, erythromycin, ciprofloxacin, moxifloxacin, gemifloxacin, tetracycline, spectinomycin, sulfamethoxazole and rifampicin (Table 1).

### Genetic characterization

One of the strains (WHO F) contained a WT *penA* allele, five strains (WHO K, W, X, Y and Z) a mosaic *penA* allele (main ESC resistance determinant),<sup>3,4,14</sup> and eight strains displayed the Asp345a alteration in the β-lactam main target penicillin-binding protein 2

(PBP2), which is observed in chromosomally mediated penicillin resistance (Table 2).<sup>3,4</sup> WHO L and WHO Y contained a PBP2 A501V and A501P alteration, respectively, which also increase the MICs of β-lactam antimicrobials including ESCs.<sup>3,4,6,7</sup> Other *penA* mutations that increase the ESC MICs are also presented. Four strains (WHO F, L, N and U) contained a WT *mtrR* promoter region sequence. The remaining strains displayed a deletion of a single nucleotide (A;  $n=8$ ) or an A→C substitution ( $n=2$ ) in the 13 bp inverted repeat of the *mtrR* promoter sequence, resulting in an increased MtrCDE efflux of substrate antimicrobials, e.g. macrolides and β-lactam antimicrobials.<sup>3,4,23</sup> Also WHO L and WHO N had an over-expressed MtrCDE efflux pump due to the *mtr*<sub>120</sub> mutation and a deletion of a single nucleotide in *mtrR*, respectively. These mutations result in an additional promoter for *mtrCDE* and a frame-shift, premature stop codon and truncated MtrR, respectively.<sup>23,44</sup> Concerning the *penB* AMR determinant, among the PorB1b strains ( $n=11$ ) 10 displayed mutations in A102 [A102D ( $n=9$ ) and A102N ( $n=1$ )] and nine additionally a G101K alteration, which mediate decreased permeability of target antimicrobials through the porin PorB1b.<sup>3,4</sup> Twelve strains carried the *ponA* mutation (*ponA1* allele) resulting in the L421P alteration in the second β-lactam target PBP1, which is observed in high-level chromosomally mediated penicillin resistance.<sup>4</sup> Of the β-lactamase-producing strains ( $n=4$ ), two (WHO M and O) carried African-type plasmid and two (WHO N and V) Asian-type plasmid, which all contained *bla*<sub>TEM-1</sub> resulting in high-level penicillin resistance.<sup>45,46</sup> In regards of fluoroquinolone resistance, one strain (WHO G) displayed only an S91F mutation in GyrA, subunit A of DNA gyrase (ciprofloxacin MIC=0.125 mg/L), one (WHO M) a GyrA S91F mutation and a GyrA D95G mutation (ciprofloxacin MIC=2 mg/L) and the remaining eight ciprofloxacin-resistant strains contained a GyrA S91F mutation, a GyrA D95G/N mutation and one or two amino acid alterations in codons 86–88 of ParC, subunit C of DNA topoisomerase IV (ciprofloxacin MIC=4–>32 mg/L).<sup>4,47</sup> One strain (WHO O) had a C1192T spectinomycin target mutation in all four alleles of the 16S rRNA gene (spectinomycin MIC >1024 mg/L<sup>48</sup>). WHO U and WHO V possessed the C2611T mutation and A2059G mutation, respectively, in all four alleles of the 23S rRNA gene, which are target mutations causing low-level and high-level resistance to azithromycin.<sup>4,26,49</sup> No azithromycin resistance mutations were found in the *rplD* or *rplV* gene (encoding ribosomal protein L4 and L22, respectively) and none of the macrolide resistance-associated genes *mefA/E* (encoding Mef efflux pump),<sup>50</sup> *ereA* and *ereB* (encoding erythromycin esterase) or *ermA-C* and *ermF* (encoding RNA methylases that block macrolides from binding to the 23S subunit target)<sup>51</sup> were identified in any of the strains. Three of the strains (WHO M, N and P) contained an H552N target mutation in RpoB (encoding RNA polymerase subunit B), resulting in high-level rifampicin resistance.<sup>52</sup> The *tet(M)*-carrying conjugative plasmids, resulting in high-level tetracycline resistance, identified in WHO G and N were of the Dutch plasmid type.<sup>53</sup> All strains except WHO F had the V57M mutation in *rpsJ*, encoding ribosomal protein S10 and involved in chromosomally mediated tetracycline resistance.<sup>54</sup> All strains except WHO F and WHO L contained the R228S mutation in the sulphonamide target dihydropteroate synthase (DHPS), encoded by *folP*, associated with sulphonamide resistance.<sup>55</sup> Finally, the promoter sequence for the *macAB* operon (encoding the MacA-MacB efflux pump) contained the –10 hexamer sequence TAGAAT in all strains. This sequence is

**Table 1.** Phenotypic characteristics of epidemiological and diagnostic relevance and antimicrobial susceptibility/resistance phenotypes displayed by the 2016 WHO *N. gonorrhoeae* reference strains (n=14)

Characteristic	WHO F <sup>a</sup>	WHO G <sup>a</sup>	WHO K <sup>a</sup>	WHO L <sup>a</sup>	WHO M <sup>a</sup>	WHO N <sup>a</sup>	WHO O <sup>a</sup>	WHO P <sup>a</sup>	WHO U	WHO V	WHO W	WHO X	WHO Y	WHO Z
NCTC number	13 477	13 478	13 479	13 480	13 481	13 482	13 483	13 484	13 817	13 818	13 819	13 820	13 821	13 822
Serogroup	PorB1a	PorB1a	PorB1b	PorB1b	PorB1b	PorB1a	PorB1b	PorB1b	PorB1b	PorB1b	PorB1b	PorB1b	PorB1b	PorB1b
Serovar	Arst	Arst	Bpyust	Bryust	Bpyust	Arst	Boys	Bopt	Bryust	Bropys	Bpyust	Bpyust	Bpyut	Bpyust
PIP production <sup>b</sup>	Pos	—	Pos	Pos	Pos	—	Pos	Pos	Pos	—	Pos	Pos	Pos	Pos
β-Lactamase (PPNG) <sup>c</sup>	—	—	—	—	Pos	Pos	Pos	—	—	Pos	—	—	—	—
Penicillin G (0.032–>32) <sup>d</sup>	S (0.032)	I (0.5)	CMRNG (2)	CMRNG (2)	PPNG <sup>c</sup> (≥32)	PPNG <sup>c</sup> (>32)	PPNG <sup>c</sup> (>32)	I (0.25)	I (0.125)	PPNG <sup>c</sup> (>32)	CMRNG (4)	CMRNG (4)	I (1)	CMRNG (2)
Ampicillin (0.032–>256) <sup>d,e</sup>	0.032	0.25	2	2	PPNG <sup>c</sup> (8)	PPNG <sup>c</sup> (4)	PPNG <sup>c</sup> (24)	0.064	0.125	PPNG <sup>c</sup> (>256)	2	2	0.5	2
Temocillin (0.064–32) <sup>d,e</sup>	0.064	1	16	4	1	1	4	1	0.5	4	8	32	8	8
Cefuroxime (0.032–16) <sup>d,e</sup>	0.064	0.5	16	8	0.5	0.25	1	0.125	0.032	1	8	8	8	8
Cefixime (<0.016–4) <sup>d</sup>	S (<0.016)	S (<0.016)	LLR (0.25)	S (0.125)	S (<0.016)	S (<0.016)	S (0.016)	S (<0.016)	S (<0.016)	S (<0.016)	LLR (0.25)	HLR (4)	HLR (2)	HLR (2)
Ceftriaxone (<0.002–2) <sup>d</sup>	S (<0.002)	S (0.008)	S (0.064)	LLR (0.25)	S (0.016)	S (0.004)	S (0.032)	S (0.004)	S (0.002)	S (0.064)	S (0.064)	HLR (2)	HLR (1)	LLR (0.5)
Ertapenem (0.004–0.125) <sup>d,e</sup>	0.004	0.008	0.125	0.032	0.016	0.008	0.032	0.008	0.004	0.012	0.064	0.064	0.008	0.032
Erythromycin (0.5–>256) <sup>d,e</sup>	0.5	1	1	2	1	0.5	1	4	>256	>256	2	2	2	4
Azithromycin (0.125–>256) <sup>d</sup>	S (0.125)	S (0.25)	S (0.25)	I (0.5)	S (0.25)	S (0.25)	S (0.25)	R (4)	R (4)	HLR (>256)	I (0.5)	I (0.5)	R (1)	R (1)
Ciprofloxacin (0.004–>32) <sup>d</sup>	S (0.004)	LLR (0.125)	HLR (>32)	HLR (>32)	R (2)	R (4)	S (0.008)	S (0.004)	S (0.004)	HLR (>32)	HLR (>32)	HLR (>32)	HLR (>32)	HLR (>32)
Gemifloxacin (0.004–16) <sup>d,e</sup>	0.004	0.125	16	8	0.5	1	0.008	0.016	0.008	4	16	16	2	8
Moxifloxacin (0.004–16) <sup>d,e</sup>	0.004	0.064	8	16	1	1	0.016	0.032	0.008	8	8	8	4	8
Spectinomycin (8–>1024) <sup>d</sup>	S (16)	S (16)	S (16)	S (16)	S (16)	S (16)	HLR (>1024)	S (8)	S (8)	S (16)	S (16)	S (16)	S (16)	S (16)
Gentamicin (4–8) <sup>d,e</sup>	4	4	4	4	4	4	4	4	4	8	4	4	8	4
Kanamycin (8–32) <sup>d,e</sup>	16	16	16	32	16	16	16	8	8	16	16	16	16	8
Tetracycline (0.25–32) <sup>d</sup>	S (0.25)	TRNG (32)	R (2)	R (2)	R (2)	TRNG (16)	R (2)	I (1)	I (1)	R (4)	R (4)	R (2)	R (4)	R (4)
Chloramphenicol (0.5–8) <sup>d,e</sup>	0.5	2	4	8	4	4	4	4	4	8	8	8	4	8
Thiamphenicol (0.25–4) <sup>d,e</sup>	0.25	0.5	2	4	4	1	2	1	2	4	4	4	4	4
Fosfomycin (8–32) <sup>d,e</sup>	32	32	16	8	32	16	32	32	32	16	16	16	16	16
Rifampicin (0.125–>32) <sup>d,e</sup>	0.125	0.5	0.5	0.5	>32	>32	0.25	>32	0.25	0.5	0.25	0.5	0.5	0.5
Sulfamethoxazole (16–>1024) <sup>d,e</sup>	64	512	128	16	128	256	128	64	32	>1024	64	128	64	128
Solithromycin (0.064–32) <sup>d,e</sup>	0.064	0.064	0.064	0.125	0.064	0.064	0.125	0.5	0.25	32	0.064	0.064	0.125	0.125
Zoliflodacin (0.032–0.125) <sup>d,e</sup>	0.032	0.064	0.064	0.064	0.064	0.125	0.064	0.125	0.064	0.064	0.064	0.064	0.064	0.064

NCTC, National Collection of Type Cultures; S, susceptible; I, intermediate susceptible; R, resistant; LLR, low-level resistant; HLR, high-level resistant; CMRNG, chromosomally mediated resistant *N. gonorrhoeae*; TRNG, plasmid-mediated high-level tetracycline-resistant *N. gonorrhoeae*.

<sup>a</sup>Includes some previously published results.<sup>23</sup> However, additional antimicrobials have been examined and some consensus MICs have slightly changed when additional MIC determinations using different MIC-determining methodologies have been performed.

<sup>b</sup>PIP-negative *N. gonorrhoeae* strains do not produce the enzyme PIP, which can result in doubtful and/or false-negative species identification of *N. gonorrhoeae* using a biochemical or enzyme-substrate test. Global transmission of PIP-negative *N. gonorrhoeae* strains has been identified.<sup>68</sup>

<sup>c</sup>PPNG, penicillinase-producing *N. gonorrhoeae* (always considered resistant to all penicillins independent of identified MIC value, which might slightly vary).

<sup>d</sup>Resistance phenotypes based on MIC (mg/L) using Etest or agar dilution and, where feasible, susceptibility/resistance breakpoints stated by EUCAST (www.eucast.org). The reported MIC values are mean MICs (rounded to whole MIC dilution) and the acceptable range of the MICs for each antimicrobial and the different strains is ±one MIC doubling dilution, i.e. when the strains are used in quality control, for example. Note: the consensus MICs shown should be used and interpreted with caution because these were derived using one method only and, consequently, may slightly differ using other methods. However, the identified resistance phenotypes (SIR categorization) should ideally be consistent between different methods.<sup>23,59</sup>

<sup>e</sup>No susceptibility/resistance breakpoints stated by EUCAST (www.eucast.org).

**Table 2.** Genetic characteristics of relevance for epidemiology, diagnostics and antimicrobial resistance in the 2016 WHO *N. gonorrhoeae* reference strains (n=14)

Characteristic	WHO F <sup>a</sup>	WHO G <sup>a</sup>	WHO K <sup>a</sup>	WHO L <sup>a</sup>	WHO M <sup>a</sup>	WHO N <sup>a</sup>	WHO O <sup>a</sup>	WHO P <sup>a</sup>	WHO U	WHO V	WHO W	WHO X	WHO Y	WHO Z
MLST ST	ST10934	ST1903	ST7363	ST1590	ST7367	ST1583	ST1902	ST8127	ST7367	ST10314	ST7363	ST7363	ST1901	ST7363
NG-MAST ST	ST3303	ST621	ST1424	ST1422	ST3304	ST556	ST495	ST3305	ST2382	ST8927	ST835	ST4220	ST1407	ST4015
<i>porA</i> pseudogene mutant <sup>24,25</sup>	—	—	—	—	—	—	—	—	yes	—	—	—	—	—
<i>cpxB</i> gene <sup>65–67</sup>	—	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
<i>pip</i> gene mutant <sup>68</sup>	—	yes	—	—	—	yes	—	—	yes	—	—	—	—	—
<i>penA</i> mosaic allele <sup>3,4,69–71</sup>	—	—	yes	—	—	—	—	—	—	—	yes	yes	yes	yes
PBP2 A311V <sup>5,70,71</sup>	—	—	—	—	—	—	—	—	—	—	—	yes	—	yes
PBP2 I312M and G545S <sup>69,71</sup>	—	—	yes	—	—	—	—	—	—	—	yes	yes	yes	yes
PBP2 V316T <sup>69,71</sup>	—	—	yes	—	—	—	—	—	—	—	yes	—	yes	yes
PBP2 V316P <sup>5,70,71</sup>	—	—	—	—	—	—	—	—	—	—	—	yes	—	—
PBP2 T483S <sup>4,70,71</sup>	—	—	—	—	—	—	—	—	—	—	—	yes	—	yes
PBP2 A501V <sup>3,4,69,71</sup>	—	—	—	yes	—	—	—	—	—	—	—	—	—	—
PBP2 A501P <sup>3,4,7,71</sup>	—	—	—	—	—	—	—	—	—	—	—	—	yes	—
PBP2 G542S <sup>3,4,71,72</sup>	—	—	—	yes	—	—	—	—	—	yes	—	—	—	—
PBP2 D345 insertion <sup>3,4,71</sup>	—	yes	—	yes	yes	yes	yes	yes	yes	yes	—	—	—	—
PBP2 P551S <sup>3,4,71,72</sup>	—	—	—	—	—	—	—	yes	—	—	—	—	—	—
<i>mtrR</i> promoter; 13 bp inverted repeat <sup>4,71,73–75</sup>	WT	deletion of A	deletion of A	WT	deletion of A	WT	deletion of A	A→C SNP in A-repeat	WT	deletion of A	deletion of A	deletion of A	deletion of A	A→C SNP in A-repeat
<i>MtrR</i> codon G45 <sup>4,73–76</sup>	WT	WT	G→D	G→D	G→D	WT	WT	NA <sup>b</sup>	WT	WT	G→D	WT	WT	WT
<i>mtr</i> <sub>120</sub> <sup>44</sup>	—	—	—	yes	—	—	—	—	—	—	—	—	—	—
<i>mtrR</i> coding region frame shift mutation <sup>4</sup>	—	—	—	—	—	deletion of A at bp 158 <sup>b</sup>	—	insertion of T at bp 60 <sup>b</sup>	—	—	—	—	—	—
<i>porB1b</i> codon G101 <sup>4,71,77,78</sup>	NA <sup>c</sup>	NA <sup>c</sup>	G→K	G→K	G→K	NA <sup>c</sup>	G→K	WT	WT	G→K	G→K	G→K	G→K	G→K
<i>porB1b</i> codon A102 <sup>4,71,77,78</sup>	NA <sup>c</sup>	NA <sup>c</sup>	A→D	A→D	A→D	NA <sup>c</sup>	A→D	A→D	WT	A→D	A→D	A→D	A→N	A→D
<i>ponA1</i> ; L421→P in PBP1 <sup>79</sup>	—	yes	yes	yes	yes	yes	yes	—	yes	yes	yes	yes	yes	yes
<i>gyrA</i> codon S91 <sup>4,47,71</sup>	WT	S→F	S→F	S→F	S→F	S→F	WT	WT	WT	S→F	S→F	S→F	S→F	S→F
<i>gyrA</i> codon D95 <sup>4,47,71</sup>	WT	WT	D→N	D→N	D→G	D→G	WT	WT	WT	D→G	D→N	D→N	D→G	D→N
<i>parC</i> codon D86 <sup>4,47,71</sup>	WT	WT	WT	D→N	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT
<i>parC</i> codon S87 <sup>4,47,71</sup>	WT	WT	S→R	WT	WT	S→I	WT	WT	S→W	S→R	S→R	S→R	S→R	S→R
<i>parC</i> codon S88 <sup>4,47,71</sup>	WT	WT	S→P	S→P	WT	WT	WT	WT	WT	WT	S→P	S→P	WT	S→P
<i>parE</i> codon G410 <sup>80</sup>	WT	G→V	WT	WT	WT	G→V	WT	WT	WT	WT	WT	WT	WT	WT
16S rRNA (bp 1192) <sup>d4,48</sup>	WT	WT	WT	WT	WT	WT	C→T	WT	WT	WT	WT	WT	WT	WT
23S rRNA (bp 2059) <sup>d4,26</sup>	WT	WT	WT	WT	WT	WT	WT	WT	WT	A→G	WT	WT	WT	WT
23S rRNA (bp 2611) <sup>d4,49</sup>	WT	WT	WT	WT	WT	WT	WT	WT	C→T	WT	WT	WT	WT	WT
<i>rpoB</i> codon H552 <sup>52,71</sup>	WT	WT	WT	WT	H→N	H→N	WT	H→N	WT	WT	WT	WT	WT	WT
<i>rpsJ</i> codon V57 <sup>54,71</sup>	WT	V→M	V→M	V→M	V→M	V→M	V→M	V→M	V→M	V→M	V→M	V→M	V→M	V→M
<i>folP</i> codon R228 <sup>55,71</sup>	WT	R→S	R→S	WT	R→S	R→S	R→S	R→S	R→S	R→S	R→S	R→S	R→S	R→S
β-Lactamase plasmid type <sup>4,45,46,71</sup>	—	—	—	—	African	Asian	African	—	—	Asian	—	—	—	—
<i>bla</i> <sub>TEM</sub> allele <sup>46</sup>	—	—	—	—	TEM-1	TEM-1	TEM-1	—	—	TEM-1	—	—	—	—
<i>tet</i> (M) plasmid type <sup>4,53,71</sup>	—	Dutch	—	—	—	Dutch	—	—	—	—	—	—	—	—

<sup>a</sup>Includes some previously published results;<sup>23</sup> however, many additional genes and mutations, and reference genomes, have been characterized in the present paper.

<sup>b</sup>NA, not applicable due to frame-shift mutation that causes a premature stop codon and truncated peptide.


<sup>c</sup>NA, not applicable because these strains were of serogroup W1 (PorB1a).

<sup>d</sup>*Escherichia coli* numbering used. Mutations found in all four alleles of the gene.

**Table 3.** General characteristics of the reference genomes of the 2016 WHO *N. gonorrhoeae* reference strains (*n*=14)

Characteristic	WHO F	WHO G	WHO K	WHO L	WHO M	WHO N	WHO O	WHO P	WHO U	WHO V	WHO W	WHO X	WHO Y	WHO Z
Genome size (bp)	2 292 467	2 167 361	2 169 846	2 168 633	2 178 344	2 172 826	2 169 062	2 173 861	2 234 269	2 221 284	2 222 386	2 171 112	2 228 980	2 229 351
No. of CDSs	2450	2299	2296	2314	2305	2300	2304	2305	2378	2366	2361	2295	2380	2368
Coding density (%)	84.8	84.5	84.6	84.5	84.5	84.6	84.6	84.6	84.8	84.8	84.7	84.5	84.8	84.6
Average gene size (bp)	793.7	796.5	799.3	791.6	798.7	798.9	796.0	797.6	796.8	795.8	797.5	799.5	794.4	796.7
GC content (%)	52.1	52.6	52.6	52.6	52.6	52.6	52.6	52.6	52.4	52.4	52.4	52.6	52.4	52.4
5S rRNA									4					
16S rRNA									4					
23S rRNA									4					
tRNAs	56	56	57	56	56	56	56	56	56	56	56	57	56	57
ncRNAs	16	15	15	15	15	15	16	16	16	16	16	16	16	16
tmRNA	1	1	1	1	1	1	1	1	1	1	1	1	1	1
No. of genes in pangenome									3478					
No. core genes									1820					
Accessory genes (%)	630 (25.7)	479 (20.8)	476 (20.7)	494 (21.3)	485 (21.0)	480 (20.9)	484 (21.0)	485 (21.0)	558 (23.5)	546 (23.1)	541 (22.9)	475 (20.7)	560 (23.5)	548 (23.1)
DNA uptake sequences (DUSs) <sup>a</sup>	1981 (1533)	1947 (1510)	1950 (1510)	1956 (1518)	1955 (1516)	1951 (1513)	1950 (1519)	1959 (1517)	1963 (1512)	1968 (1518)	1954 (1509)	1949 (1510)	1973 (1522)	1959 (1512)
Number of plasmids	0	2	1	2	3	3	3	1	1	2	2	1	1	1

<sup>a</sup>Total of the 10-mer DUS sequence GCCGTCTGAA (no. of the 12-mer ATGCCGTCTGAA). Note: the 10-mer sequence is included in the 12-mer.



characteristic of the *macAB* promoter sequence in gonococci and meningococci and has a dampening effect on the *macAB* transcription compared with a  $-10$  TATAAT sequence.<sup>56</sup> No mutations modulating transcription were found in any of the strains in the putative  $-35$  promoter hexamer sequence (CTGACG) of the promoter sequence for the *norM* gene (encoding the NorM efflux pump) or in its ribosome binding site (TGAA).<sup>57</sup>

Of importance for phenotypic and/or molecular detection of gonococci, *cppB* (WHO F), *pip* (WHO G, N and U) and *porA* (WHO U) mutant strains were represented. Finally, the strains displayed 14 different *porB* alleles, 14 divergent NG-MAST STs and 10 different MLST STs. Notably, the MLST ST7363 and ST1901, and NG-MAST ST1407, were represented, which are internationally spread MDR clones that account for most of the ESC resistance globally (Table 2).<sup>3,4,6,7,10,11,14,19</sup>

### Reference genome characterization

The general characteristics of the reference genomes are summarized in Table 3. The genome size ranged from 2 167 361 to 2 292 467 bp. The number of coding sequences (CDSs) after manual curation varied from 2295 to 2450 with an average CDS size of 796.6 bp. The number of core genes was 1820 and accessory genes ranged from 475 to 630. In Figure 1(a and b) BLAST atlases of the 14 reference genomes and all identified plasmid sequences, respectively, are displayed. Briefly, the reference genomes showed relatively high genomic similarity among all strains with the exception of two large insertions in WHO F and the presence or absence of the gonococcal genomic island (GGI).<sup>58</sup> The insertions in WHO F each include 34 almost identical predicted CDSs (31 984 bp) mainly containing an apparently complete type IV secretion system, a *vapD* virulence gene and *xerC* recombinase inserted into a tRNA-Asn element, with only weak matches to other sequences in the NCBI non-redundant nt database. Other regions with low genetic conservation corresponded to mobile genetic elements and prophages (Figure 1a).

Figure 2 shows the phylogenetic relationship among all the reference core genomes ( $n=14$ , 1820 loci). The number of SNPs between the core genomes is shown on the branches. The average pairwise SNP distance was estimated as 2962 SNPs, with WHO X and WHO Z being the most similar strains (272 SNPs) and WHO F and WHO U the most distant (4969 SNPs). Figure S1 and Table S2, show the pairwise SNP distances among all 14 reference core genomes.

Between none and three plasmids were detected in each strain (Table 3), either from the PacBio or Illumina assemblies. The cryptic plasmid was found in all strains except WHO F, and the  $\beta$ -lactamase plasmid containing a *bla*<sub>TEM-1</sub> gene was found in four of the isolates (WHO M, N, O and V; Figure 1b), producing plasmid-mediated high-level penicillin resistance (Tables 1 and 2). The *tet(M)*-carrying conjugative plasmid causing high-level tetracycline resistance through

the *tet(M)* gene was found in WHO G and WHO N (Tables 1 and 2). However, WGS also identified the conjugative plasmid in four additional strains (WHO L, M, O and W), although these were lacking the *tet(M)* resistance gene (Figure 1b).


### Discussion

In this study, the 2016 WHO *N. gonorrhoeae* reference strains and their detailed phenotypic, genetic and reference genome characteristics are reported. The utility of these strains includes quality control and quality assurance practices in the WHO global and other GASPs. Comprehensive description regarding applications and use of WHO reference strains in GASPs has previously been published.<sup>23,59</sup> The strains include all important susceptible, intermediate susceptible and resistant phenotypes and the ranges of resistances seen for most antimicrobials previously or currently recommended in different guidelines and/or used in the gonorrhoea treatment globally. However, the consensus MIC values (Table 1) were determined using one AMR method only. Accordingly, these MIC values may differ slightly using other AMR methods, though the resistance phenotypes should be consistent. It is strongly recommended that laboratories using the superseded WHO A–E reference strains or the 2008 WHO gonococcal reference strains<sup>23</sup> update to the current 2016 panel. The 2016 WHO gonococcal reference strains will be available through WHO sources and the NCTC ([www.phe-culturecollections.org.uk](http://www.phe-culturecollections.org.uk)).

In many countries, NAATs are replacing culture for gonococcal detection and, accordingly, genetic detection of AMR determinants to predict resistance or susceptibility to antimicrobials has become of increased interest, both for future AMR surveillance and, ideally, also to guide individually tailored treatment.<sup>4,60,61</sup> Thus, the genetic AMR determinants, acting singly or collaboratively, that mediate the different AMR phenotypes in the 2016 WHO gonococcal reference strains were characterized in detail and included most known gonococcal AMR determinants. These reference strains are designed for internal and external quality assurance and quality control components of both gonococcal phenotypic AMR surveillance and future surveillance using molecular AMR prediction. Molecular AMR methods can never entirely replace phenotypic AMR testing because they only detect identified AMR determinants and new ones will continue to evolve. However, the molecular prediction of AMR or susceptibility can supplement the conventional culture-based phenotypic AMR surveillance. For example, ciprofloxacin susceptibility is relatively straightforward to predict, azithromycin resistance can be indicated and detection of a mosaic *penA* gene can predict decreased susceptibility or resistance to ESCs.<sup>4,60–62</sup> However, due to the many different genes, mutations and accumulation of mutations causing, for example, ESC resistance the molecular methods will not be able to predict an exact MIC of the antimicrobials. However,

**Figure 1.** BLAST atlas of the 2016 WHO *N. gonorrhoeae* reference genomes ( $n=14$ ). (a) A genome comparison of the 2016 WHO reference strains presented in this study using WHO F<sup>23</sup> as reference and (b) a comparison of the up to three plasmids (named pCryptic, pBlaTEM and pConjugative<sup>65,81,82</sup>) identified in the same strains. WHO G pCryptic (cryptic plasmid), WHO M pBlaTEM ( $\beta$ -lactamase-producing plasmid) and WHO G pConjugative [conjugative plasmid including *tet(M)* in WHO G and N] were used as references, respectively. For each, GC skew is shown in the inner rings. The position in the genomes is shown for genetic resistance determinants and loci used for molecular diagnostics and epidemiological characterization, i.e. NG-MAST STs and MLST STs. The presence of the GGI<sup>58</sup> is indicated in red. An approximately 500 bp region with lower nucleotide conservation ( $\sim 75\%$  identity) is shown with lighter colours in WHO M and WHO O pBlaTEM plasmids corresponding to a hypothetical protein.





**Figure 2.** Phylogenetic tree of the 2016 WHO *N. gonorrhoeae* reference core genomes ( $n = 14$ ). The tree is rooted using an *N. meningitidis* genome as outgroup (not shown). The number of SNPs is shown on each branch. Highlighted nodes show bootstrap supports higher than 80%. Typing, genomic features and antibiotic resistance patterns of the 2016 WHO reference strains are shown alongside the tree. Only antimicrobials with a SIR categorization assigned are displayed.

this is not essential if the susceptibility/resistance phenotypes can be predicted by targeting the main AMR determinants. The sensitivity and/or specificity of the AMR prediction will also vary in different settings due to the myriad of gonococcal strains circulating and some cross-reactivity with non-gonococcal *Neisseria* species, particularly in pharyngeal specimens, might be unavoidable.<sup>3,4,60-62</sup> Despite these limitations, molecular prediction of AMR or susceptibility enables testing of substantially more gonococcal samples (including NAAT samples), assessing the spread of genetic potential for AMR development and identifying settings where targeted culture-based phenotypic AMR testing should be initiated. WGS and other novel molecular technologies will likely revolutionize the molecular AMR prediction in gonococci. Ultimately, point-of-care (POC) genetic AMR methods, combined with gonococcal detection, might be used to guide individually tailored treatment of gonorrhoea, which can ensure rational use of antimicrobials (including sparing last-line antimicrobials) and affect the control of both gonorrhoea and AMR.

In recent years, WGS, providing a dramatic increase in resolution, has become more cost-effective and user-friendly. WGS has the potential to revolutionize investigations into gonococcal evolution and population genetics, to identify and track specific strains spreading globally in particular populations and/or in core groups, to identify temporal and geographical changes in strain types as well as the emergence and transmission of individual strains (e.g. MDR ones), to investigate strain identity in contact tracing, test-of-cure and suspected treatment failures, to confirm presumed epidemiological connections or discount isolates from suspected clusters and outbreaks, and to predict AMR or susceptibility in future AMR surveillance.<sup>63</sup> However, when WGS becomes widely used internationally it is crucial that appropriate, validated and finished gonococcal reference genomes are available. Consequently, we present the fully characterized, annotated and finished reference genomes of the 2016 WHO gonococcal reference strains, to enable quality assurance of *N. gonorrhoeae* WGS analysis.

The 2016 WHO *N. gonorrhoeae* reference strain panel includes the previously published 2008 WHO gonococcal reference strains ( $n=8$ ).<sup>23</sup> However, in the present study these strains were subjected to further exceedingly detailed analyses. For example, the susceptibility/resistance to additional antimicrobials (sulfamethoxazole, chloramphenicol, gemifloxacin, moxifloxacin, solithromycin, zoliflodacin, fosfomicin, temocillin and thiamphenicol), additional molecular AMR or diagnostic determinants (mutations in the *rpsJ*,<sup>54</sup> *folP*,<sup>55</sup> 23S rRNA,<sup>4,26,49</sup> *rplD*, *rplV* and *bla*<sub>TEM</sub> genes<sup>4,46</sup> and additional *penA* mutations of interest for ESC resistance,<sup>3,4</sup> as well as the presence of *macAB*<sup>56</sup> and *norM*<sup>57</sup> promoter mutations, the *mtr*<sub>120</sub> mutation,<sup>44</sup> *ermA*, *ermB*, *ermC* and *ermF* genes,<sup>51,64</sup> *ereA* and *ereB* genes, *mefA/E* genes<sup>50</sup> that can cause macrolide resistance, the *cppB* gene,<sup>65-67</sup> the mutated *porA* pseudogene,<sup>24,25</sup> the mutated *pip* gene<sup>68</sup> and the GGI<sup>58</sup>) and further molecular epidemiological characteristics (MLST STs) were investigated. Furthermore, finished reference genomes were produced, fully annotated and characterized. The six novel WHO reference strains (WHO U, V, W, X, Y and Z) represent phenotypes and genotypes not available when the earlier reference strain panel<sup>23</sup> was developed. Now included are gonococcal strains with low-level to high-level ESC resistance due to different ESC resistance *penA* mutations and associated with both cefixime and ceftriaxone treatment failures. These will be of particular value for enhanced

validation of the phenotypic AMR testing, especially monitoring ESC MIC drifts over time. The 2016 WHO reference strains also include a gonococcal strain with high-level azithromycin resistance, due to the A2059G mutation in all four alleles of the 23S rRNA gene,<sup>26</sup> and one with a mutated *porA* pseudogene (*N. meningitidis porA* gene sequences resulting in false-negative results in *porA*-based gonococcal NAATs).<sup>24,25</sup>

In conclusion, the 2016 WHO *N. gonorrhoeae* reference strains were extensively characterized both phenotypically and genetically, including characterizing the reference genomes, and are intended for internal and external quality assurance and quality control purposes in laboratory investigations. These strains should prove particularly useful in WHO global and other GASPs (to allow valid intra- and inter-laboratory comparisons of AMR data derived by different methods in various countries), but also in phenotypic (e.g. culture, species determination) and molecular diagnostics, genetic AMR detection, molecular epidemiology and as fully characterized, annotated and finished reference genomes in WGS analysis, transcriptomics, proteomics and other molecular technologies and data analysis. When additional resistant phenotypes and/or genotypes emerge, novel WHO gonococcal reference strains will be selected, characterized and added to the panel of existing strains.

## Acknowledgements

We are very grateful to Janice Lo and Patrice Sednaoui for providing the WHO W strain and the WHO Y strain, respectively.

## Funding

This study was supported by grants from: the Department of Reproductive Health and Research, WHO Headquarters, Geneva, Switzerland; the Australian Government Department of Health and the Department of Microbiology, South Eastern Area Laboratory Services, New South Wales, Australia; and Örebro County Council Research Committee and Foundation for Medical Research at Örebro University Hospital, Sweden. WGS and analysis at the Wellcome Trust Sanger Institute was supported through Wellcome Trust grant number 098051. Y. G. was supported by K08-AI104767 from the National Institutes of Health/National Institute of Allergy and Infectious Diseases.

## Transparency declarations

None to declare.

## Supplementary data

Tables S1 and S2 and Figure S1 are available as Supplementary data at JAC Online (<http://jac.oxfordjournals.org/>).

## References

1 Newman L, Rowley J, Vander Hoorn S *et al*. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. *PLoS One* 2015; **10**: e0143304.

- 2 WHO. *Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae*. 2012. [http://whqlibdoc.who.int/publications/2012/9789241503501\\_eng.pdf?ua=1](http://whqlibdoc.who.int/publications/2012/9789241503501_eng.pdf?ua=1).
- 3 Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhoea. *Future Microbiol* 2012; **7**: 1401–22.
- 4 Unemo M, Shafer WM. Antimicrobial resistance in *Neisseria gonorrhoeae* in the 21st century: past, evolution, and future. *Clin Microbiol Rev* 2014; **27**: 587–613.
- 5 Ohnishi M, Golparian D, Shimuta K et al. Is *Neisseria gonorrhoeae* initiating a future era of untreatable gonorrhoea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. *Antimicrob Agents Chemother* 2011; **55**: 3538–45.
- 6 Cámara J, Serra J, Ayats J et al. Molecular characterization of two high-level ceftriaxone-resistant *Neisseria gonorrhoeae* isolates detected in Catalonia, Spain. *J Antimicrob Chemother* 2012; **67**: 1858–60.
- 7 Unemo M, Golparian D, Nicholas R et al. High-level cefixime- and ceftriaxone-resistant *Neisseria gonorrhoeae* in France: novel *penA* mosaic allele in a successful international clone causes treatment failure. *Antimicrob Agents Chemother* 2012; **56**: 1273–80.
- 8 Lahra MM, Ryder N, Whiley DM. A new multidrug-resistant strain of *Neisseria gonorrhoeae* in Australia. *N Engl J Med* 2014; **371**: 1850–1.
- 9 Chen SC, Yin YP, Dai XQ et al. Antimicrobial resistance, genetic resistance determinants for ceftriaxone and molecular epidemiology of *Neisseria gonorrhoeae* isolates in Nanjing, China. *J Antimicrob Chemother* 2014; **69**: 2959–65.
- 10 Unemo M, Golparian D, Sary A et al. First *Neisseria gonorrhoeae* strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. *Euro Surveill* 2011; **16**: pii=19998.
- 11 Golparian D, Ohlsson A, Janson H et al. Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. *Euro Surveill* 2014; **19**: pii=20862.
- 12 Chen YM, Stevens K, Tideman R et al. Failure of ceftriaxone 500 mg to eradicate pharyngeal gonorrhoea, Australia. *J Antimicrob Chemother* 2013; **68**: 1445–7.
- 13 Read PJ, Limnios EA, McNulty A et al. One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500 mg ceftriaxone in Sydney, Australia. *Sex Health* 2013; **10**: 460–2.
- 14 Unemo M. Current and future antimicrobial treatment of gonorrhoea—the rapidly evolving *Neisseria gonorrhoeae* continues to challenge. *BMC Infect Dis* 2015; **15**: 364.
- 15 CDC. *Cephalosporin-Resistant Neisseria gonorrhoeae Public Health Response Plan*. 2012; 1–43. <http://www.cdc.gov/std/gonorrhoea/default.htm>.
- 16 ECDC. *Response Plan to Control and Manage the Threat of Multidrug-Resistant Gonorrhoea in Europe*. 2012; 1–23. [www.ecdc.europa.eu/en/publications/Publications/1206-ECDC-MDR-gonorrhoea-response-plan.pdf](http://www.ecdc.europa.eu/en/publications/Publications/1206-ECDC-MDR-gonorrhoea-response-plan.pdf).
- 17 Ndowa F, Lusti-Narasimhan M, Unemo M. The serious threat of multidrug-resistant and untreatable gonorrhoea: the pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health. *Sex Transm Infect* 2012; **88**: 317–8.
- 18 Cole MJ, Spiteri G, Jacobsson S et al. Is the tide turning again for cephalosporin resistance in *Neisseria gonorrhoeae* in Europe? Results from the 2013 European surveillance. *BMC Infect Dis* 2015; **15**: 321.
- 19 Chisholm SA, Unemo M, Quaye N et al. Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. *Euro Surveill* 2013; **18**: pii=20358.
- 20 Kirkcaldy RD, Hook EW 3rd, Soge OO et al. Trends in *Neisseria gonorrhoeae* susceptibility to cephalosporins in the United States, 2006–2014. *JAMA* 2015; **314**: 1869–71.
- 21 Ison CA, Town K, Obi C et al. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007–2011. *Lancet Infect Dis* 2013; **13**: 762–8.
- 22 Reyn A, Bentzon MW, Thayer JD et al. Results of comparative experiments using different methods for determining the sensitivity of *Neisseria gonorrhoeae*. *Bull WHO* 1965; **32**: 477–502.
- 23 Unemo M, Fasth O, Fredlund H et al. Phenotypic and genetic characterization of the 2008 WHO *Neisseria gonorrhoeae* reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. *J Antimicrob Chemother* 2009; **63**: 1142–51.
- 24 Ison C, Golparian D, Saunders P et al. Evolution of *Neisseria gonorrhoeae* is a continuing challenge for molecular detection of gonorrhoea—false negative gonococcal *porA* mutants are spreading internationally. *Sex Transm Infect* 2013; **89**: 197–201.
- 25 Golparian D, Johansson E, Unemo M. Clinical *Neisseria gonorrhoeae* isolate with a *N. meningitidis porA* gene and no prolyliminopeptidase activity, Sweden, 2011—danger of false-negative genetic and culture diagnostic results. *Euro Surveill* 2012; **17**: pii=20102.
- 26 Unemo M, Golparian D, Hellmark B. First three *Neisseria gonorrhoeae* isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-antimicrobial regimens for treatment of gonorrhoea? *Antimicrob Agents Chemother* 2013; **58**: 624–5.
- 27 Lo JYC, Ho KM, Leung AOC et al. Cefitibuten resistance and treatment failure in gonococcal infection. *Antimicrob Agent Chemother* 2008; **52**: 3564–7.
- 28 Unemo M, Olcén P, Berglund T et al. Molecular epidemiology of *Neisseria gonorrhoeae*: sequence analysis of the *porB* gene confirms presence of two circulating strains. *J Clin Microbiol* 2002; **40**: 3741–9.
- 29 Unemo M, Sjöstrand A, Akhras M et al. Molecular characterisation of *Neisseria gonorrhoeae* identifies transmission and resistance of one ciprofloxacin resistant strain. *APMIS* 2007; **115**: 231–41.
- 30 Jolley KA. Multi-locus sequence typing. In: Pollard AJ, Maiden MC, eds. *Meningococcal Disease: Methods and Protocols*. Totowa, NJ: Humana Press, 2001; 173–86.
- 31 Hunt M, Silva ND, Otto TD et al. Circlator: automated circularization of genome assemblies using long sequencing reads. *Genome Biol* 2015; **16**: 294.
- 32 Chin CS, Alexander DH, Marks P et al. Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data. *Nat Methods* 2013; **10**: 563–9.
- 33 Makendi C, Page AJ, Wren BW et al. A phylogenetic and phenotypic analysis of *Salmonella enterica* serovar *weltevreden*, an emerging agent of diarrheal disease in tropical regions. *PLoS Negl Trop Dis* 2016; **10**: e0004446.
- 34 Carver TJ, Rutherford KM, Berriman M et al. ACT: the Artemis Comparison Tool. *Bioinformatics* 2005; **21**: 3422–3.
- 35 Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* 2010; **26**: 589–95.
- 36 Li H. Minimap and miniasm: fast mapping and de novo assembly for noisy long sequences. *Bioinformatics* 2016; doi:10.1093/bioinformatics/btw152.
- 37 Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 2014; **30**: 2068–9.
- 38 Rutherford K, Parkhill J, Crook J et al. Artemis: sequence visualization and annotation. *Bioinformatics* 2000; **16**: 944–5.
- 39 Jones P, Binns D, Chang HY et al. InterProScan 5: genome-scale protein function classification. *Bioinformatics* 2014; **30**: 1236–40.
- 40 Camacho C, Coulouris G, Avagyan V et al. BLAST+: architecture and applications. *BMC Bioinformatics* 2009; **10**: 421.

- 41** Alikhan NF, Petty NK, Ben Zakour NL *et al.* BLAST Ring Image Generator (BRIG): simple prokaryote genome comparisons. *BMC Genomics* 2011; **12**: 402.
- 42** Page AJ, Cummins CA, Hunt M *et al.* Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics* 2015; **31**: 3691–3.
- 43** Tamura K, Stecher G, Peterson D *et al.* MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. *Mol Biol Evol* 2013; **30**: 2725–9.
- 44** Ohneck EA, Zalucki YM, Johnson PJ *et al.* A novel mechanism of high-level, broad-spectrum antibiotic resistance caused by a single base pair change in *Neisseria gonorrhoeae*. *MBio* 2011; **2**: e00187–11.
- 45** Palmer HM, Leeming JP, Turner A. A multiplex polymerase chain reaction to differentiate  $\beta$ -lactamase plasmids of *Neisseria gonorrhoeae*. *J Antimicrob Chemother* 2000; **45**: 777–82.
- 46** Muhammad I, Golparian D, Dillon JA *et al.* Characterisation of *bla*<sub>TEM</sub> genes and types of  $\beta$ -lactamase plasmids in *Neisseria gonorrhoeae*—the prevalent and conserved *bla*<sub>TEM</sub>-135 has not recently evolved and existed in the Toronto plasmid from the origin. *BMC Infect Dis* 2014; **14**: 454.
- 47** Trees DL, Sandul AL, Peto-Mesola V *et al.* Alterations within the quinolone resistance-determining regions of GyrA and ParC of *Neisseria gonorrhoeae* isolated in the Far East and the United States. *Int J Antimicrob Agents* 1999; **12**: 325–32.
- 48** Galimand M, Gerbaud G, Courvalin P. Spectinomycin resistance in *Neisseria* spp. due to mutations in 16S rRNA. *Antimicrob Agents Chemother* 2000; **44**: 1365–6.
- 49** Ng L-K, Martin I, Liu G *et al.* Mutation in 23S rRNA associated with macrolide resistance in *Neisseria gonorrhoeae*. *Antimicrob Agents Chemother* 2002; **46**: 3020–5.
- 50** Luna VA, Cousin S Jr, Whittington WL *et al.* Identification of the conjugative *mef* gene in clinical *Acinetobacter junii* and *Neisseria gonorrhoeae* isolates. *Antimicrob Agents Chemother* 2000; **44**: 2503–6.
- 51** Cousin SL Jr, Whittington WL, Roberts MC. Acquired macrolide resistance genes and the 1 bp deletion in the *mtrR* promoter in *Neisseria gonorrhoeae*. *J Antimicrob Chemother* 2003; **51**: 131–3.
- 52** Nolte O, Müller M, Reitz S *et al.* Description of new mutations in the *rpoB* gene in rifampicin-resistant *Neisseria meningitidis* selected *in vitro* in a stepwise manner. *J Med Microbiol* 2003; **52**: 1077–81.
- 53** Turner A, Gough KR, Leeming JP. Molecular epidemiology of *tetM* genes in *Neisseria gonorrhoeae*. *Sex Transm Infect* 1999; **75**: 60–6.
- 54** Hu M, Nandi S, Davies C *et al.* High-level chromosomally mediated tetracycline resistance in *Neisseria gonorrhoeae* results from a point mutation in the *rpsJ* gene encoding ribosomal protein S10 in combination with the *mtrR* and *penB* resistance determinants. *Antimicrob Agents Chemother* 2005; **49**: 4327–34.
- 55** Fiebelkorn KR, Crawford SA, Jorgensen JH. Mutations in *folP* associated with elevated sulfonamide MICs for *Neisseria meningitidis* clinical isolates from five continents. *Antimicrob Agents Chemother* 2005; **49**: 536–40.
- 56** Rouquette-Loughlin CE, Balthazar JT, Shafer WM. Characterization of the MacA-MacB efflux system in *Neisseria gonorrhoeae*. *J Antimicrob Chemother* 2005; **56**: 856–80.
- 57** Rouquette-Loughlin CE, Dunham SA, Kuhn M *et al.* The NorM efflux pump of *Neisseria gonorrhoeae* and *Neisseria meningitidis* recognizes antimicrobial cationic compounds. *J Bacteriol* 2003; **185**: 1101–6.
- 58** Hamilton HL, Domínguez NM, Schwartz KJ *et al.* *Neisseria gonorrhoeae* secretes chromosomal DNA via a novel type IV secretion system. *Mol Microbiol* 2005; **55**: 1704–21.
- 59** WHO GASP Document 'Rationale and Applications for the Current (2008) WHO Panel of *Neisseria gonorrhoeae* for Antimicrobial Resistance Surveillance for Public Health Purposes, and Instructions for Their Use'. Technical document D007-0408-1#1. Sydney: WHO Collaborating Centre for STD, 2008.
- 60** Low N, Unemo M. Molecular tests for the detection of antimicrobial resistant *Neisseria gonorrhoeae*: when, where, and how to use? *Curr Opin Infect Dis* 2016; **29**: 45–51.
- 61** Goire N, Lahra MM, Chen M *et al.* Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. *Nat Rev Microbiol* 2014; **12**: 223–9.
- 62** Whiley DM, Lahra MM, Unemo M. Prospects of untreatable gonorrhoea and ways forward. *Future Microbiol* 2015; **10**: 313–6.
- 63** Unemo M, Dillon JA. Review and international recommendation of methods for typing *Neisseria gonorrhoeae* isolates and their implications for improved knowledge of gonococcal epidemiology, treatment, and biology. *Clin Microbiol Rev* 2011; **24**: 447–58.
- 64** Roberts MC, Chung WO, Roe D *et al.* Erythromycin-resistant *Neisseria gonorrhoeae* and oral commensal *Neisseria* spp. carry known rRNA methylase genes. *Antimicrob Agents Chemother* 1999; **43**: 1367–72.
- 65** Korch C, Hagblom P, Ohman H *et al.* Cryptic plasmid of *Neisseria gonorrhoeae*: complete nucleotide sequence and genetic organization. *J Bacteriol* 1985; **163**: 430–8.
- 66** Ho BS, Feng WG, Wong BK *et al.* Polymerase chain reaction for the detection of *Neisseria gonorrhoeae* in clinical samples. *J Clin Pathol* 1992; **45**: 439–42.
- 67** Lum G, Freeman K, Nguyen NL *et al.* A cluster of culture positive gonococcal infections but with false negative *cppB* gene based PCR. *Sex Transm Infect* 2005; **81**: 400–2.
- 68** Unemo M, Palmer HM, Blackmore T *et al.* Global transmission of prolyliminopeptidase-negative *Neisseria gonorrhoeae* strains: implications for changes in diagnostic strategies. *Sex Transm Infect* 2007; **83**: 47–51.
- 69** Tomberg J, Unemo M, Davies C *et al.* Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in *Neisseria gonorrhoeae*: role of epistatic mutations. *Biochemistry* 2010; **49**: 8062–70.
- 70** Tomberg J, Unemo M, Ohnishi M *et al.* Identification of amino acids conferring high-level resistance to expanded-spectrum cephalosporins in the *penA* gene from *Neisseria gonorrhoeae* strain H041. *Antimicrob Agents Chemother* 2013; **57**: 3029–36.
- 71** Unemo M, Nicholas RA, Jerse AE *et al.* Molecular mechanisms of antibiotic resistance expressed by the pathogenic *Neisseria*. In: Davies JK, Kahler CM, eds. *Pathogenic Neisseria: Genomics, Molecular Biology and Disease Intervention*. London: Caister Academic Press, 2014; 161–92.
- 72** Whiley DM, Goire N, Lambert SB *et al.* Reduced susceptibility to ceftriaxone in *Neisseria gonorrhoeae* is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-binding protein 2. *J Antimicrob Chemother* 2010; **65**: 1615–8.
- 73** Folster JP, Johnson PJ, Jackson L *et al.* MtrR modulates *rpoH* expression and levels of antimicrobial resistance in *Neisseria gonorrhoeae*. *J Bacteriol* 2009; **191**: 287–97.
- 74** Veal WL, Nicholas RA, Shafer WM. Overexpression of the MtrC-MtrD-MtrE efflux pump due to an *mtrR* mutation is required for chromosomally mediated penicillin resistance in *Neisseria gonorrhoeae*. *J Bacteriol* 2002; **184**: 5619–24.
- 75** Zarantonelli L, Borthagaray G, Lee EH *et al.* Decreased azithromycin susceptibility of *Neisseria gonorrhoeae* due to *mtrR* mutations. *Antimicrob Agents Chemother* 1999; **43**: 2468–72.
- 76** Hagman KE, Pan W, Spratt BG *et al.* Resistance of *Neisseria gonorrhoeae* to antimicrobial hydrophobic agents is modulated by the *mtrRCDE* efflux system. *Microbiology* 1995; **141**: 611–22.
- 77** Olesky M, Hobbs M, Nicholas RA. Identification and analysis of amino acid mutations in porin IB that mediate intermediate-level resistance to penicillin and tetracycline in *Neisseria gonorrhoeae*. *Antimicrob Agents Chemother* 2002; **46**: 2811–20.

**78** Olesky M, Zhao S, Rosenberg RL et al. Porin-mediated antibiotic resistance in *Neisseria gonorrhoeae*: ion, solute, and antibiotic permeation through PIB proteins with *penB* mutations. *J Bacteriol* 2006; **188**: 2300–8.

**79** Ropp PA, Hu M, Olesky M et al. Mutations in *ponA*, the gene encoding penicillin-binding protein 1, and a novel locus, *penC*, are required for high-level chromosomally mediated penicillin resistance in *Neisseria gonorrhoeae*. *Antimicrob Agents Chemother* 2002; **46**: 769–77.

**80** Lindbäck E, Rahman M, Jalal S et al. Mutations in *gyrA*, *gyrB*, *parC*, and *parE* in quinolone-resistant strains of *Neisseria gonorrhoeae*. *APMIS* 2002; **110**: 651–7.

**81** Pachulec E, van der Does C. Conjugative plasmids of *Neisseria gonorrhoeae*. *PLoS One* 2010; **5**: e9962.

**82** Pagotto F, Aman AT, Ng LK et al. Sequence analysis of the family of penicillinase-producing plasmids of *Neisseria gonorrhoeae*. *Plasmid* 2000; **43**: 23–34.